Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15935046 | 0.85 | CYP11B1 (0.36) | GABRG2GABRB3GABRA5GABRA3CYP11B1 | |
| SCHEMBL15923680 | 0.79 | ELOVL1 (0.41) | — | |
| SCHEMBL15924165 | 0.78 | CYP11B2 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL24921150 | 0.75 | TDO2 (0.34) | GABRG2GABRB3GABRA5GABRA3CYP11B1 | |
| SCHEMBL15923995 | 0.69 | MPO (0.33) | — | |
| SCHEMBL15832231 | 0.69 | RAB9A (0.41) | GABRG2GABRB3GABRA5GABRA3CYP11B1 | |
| SCHEMBL15819955 | 0.68 | GABRG2 (0.35) | GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL19132899 | 0.67 | NOTUM (0.40) | GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL24920389 | 0.66 | GABRG2 (0.38) | GABRG2GABRB3GABRA5GABRA3CYP11B1 | |
| SCHEMBL15924399 | 0.66 | NOTUM (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934538-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2021-03-31 | — | — | EP | disclosed |
| US-9708308-B2 | Factor IXa inhibitors | MERCK SHARP DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708308-B2 | Factor IXa inhibitors | MERCK SHARP DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708308-B2 | Factor IXa inhibitors | MERCK SHARP DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150322056-A1 | Factor IXa Inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150322056-A1 | Factor IXa Inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150322056-A1 | Factor IXa Inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| EP-2934538-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014120346-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120346-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322056-A1 | Factor IXa Inhibitors | F9, F12, F8 | GABRG2 2709/4885GABRB3 2498/4885GABRA5 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.